Signet-ring cell carcinomas are malignant dedifferentiated carcinomas, which are frequently found in the stomach. We previously demonstrated that a 200 kDa protein is often constitutively phosphorylated on tyrosine and bound to phosphatidylinositol 3-kinase (PI3-kinase) in signetring cell carcinoma cells. In this study, we purified the 200 kDa protein from an extract of NUGC-4 cells, a cell line of signet-ring cell carcinoma, and identified it as ErbB3. ErbB3 was found to be phosphorylated selectively in dedifferentiated adenocarcinoma cell lines among various gastric cancer cell lines. Expression of a constitutively active chimeric receptor consisting of ErbB2 and ErbB3 in HCC2998 cells, a highly differentiated adenocarcinoma cell line, revealed that the signaling triggered by phosphorylation of ErbB3 was important for dedifferentiated phenotypes such as loss of cell-cell interaction and high expression of MUC1/DF3 antigen, a marker of the malignant tumors. Taken together, activation of ErbB3 pathway may contribute to the development of dedifferentiated carcinomas.
Introduction
Adenocarcinomas of the stomach are classified into two major types: highly differentiated/intestinal type and poorly differentiated/diffuse type. Signet-ring cell carcinoma is one of the most malignant gastric carcinomas, classified histologically as a poorly differentiated adenocarcinoma. These two types of adenocarcinomas are likely to pass through common early stages, such as amplification of the cyclin E gene and genetic alteration of p53 (Sakaguchi et al., 1998) . However, they undergo some different genetic alterations. Amplification of the ErbB2 gene (Tokunaga et al., 1995) , mutations of the K-ras gene, and inactivation of APC (Isogaki et al., 1999) are preferentially associated with highly differentiated forms. On the other hand, hypermethylation of the promoter or mutations in the coding sequence are often found in the E-cadherin gene; these reduce the activity of its product in most poorly differentiated adenocarcinomas. Overexpression and activation of the C-met/HGF receptor and the K-sam/FGF receptor are also reported in poorly differentiated adenocarcinomas (Tahara, 1993) . However, the molecular pathogenesis of this tumor type, which causes its malignant nature, remains largely unknown.
Phosphatidylinositol 3-kinase (PI3-kinase) produces PI 3,4,5-triphosphate (PI 3,4,5-P 3 ) by phosphorylation of PI 4,5-biphosphate (PI 4,5-P 2 ). PI 3,4,5-P 3 , as well as PI 3,4-P 2 , which may be produced by dephosphorylation of PI 3,4,5-P 3 , have been shown to be involved in various cell responses. Many target molecules of these lipids have been reported so far, including Akt, a serine threonine protein kinase (Burgering and Coffer, 1995) , and Rac guanine nucleotide exchange factors (GEFs) (Han et al., 1998; Sander et al., 1998) . Involvement of PI3-kinase in the development of tumors has been a matter of great interest, since the avian sarcoma 16 (ASV16) genome was reported to encode a catalytic subunit of . Overexpression of v-p3k protein as well as its cellular counterpart results in activation of Akt to form hemangiosarcomas in chickens (Chang et al., 1997) . PTEN, a tumor suppressor, has been shown to be a phosphatase that dephosphorylates the 3 0 position of PI 3,4,5-P 3 to produce PI 4,5-P 2 (Maehama and Dixon, 1998) , which may inhibit the activation of Akt to suppress the signal of cell survival (Klippel et al., 1997) . Loss of PTEN may result in abnormal growth or immortality of the cells that may lead to formation of tumors. In addition to these findings, PIK3CA, a gene for p110 a, has been reported to be amplified in human ovarian cancers (Shayesteh et al., 1999) and cervical cancers (Ma et al., 2000) . These findings support the idea that PI3-kinase can contribute to the formation of tumors.
In a previous study, we reported that PI3-kinase was activated by binding to a 200 kDa protein phosphorylated on tyrosine in native signet-ring cell carcinoma cell lines (Kobayashi et al., 1999) . The aim of this study was to identify the 200 kDa protein and to investigate its roles in signet-ring cell carcinomas.
Results
Purification of the PI3-kinase-binding protein p200
As we previously reported, PI3-kinase was found to be bound to a 200 kDa protein (p200) that was phosphorylated on tyrosines in four out of five signet-ring cell carcinoma lines (p200-positive cells) (Figure 1a) . No p200 was detected in moderately or highly differentiated carcinoma cell lines and also in one signet-ring carcinoma cell line, HSC60 (p200-negative cells). Although phosphotyrosine-containing proteins were detected in MKN28 and MKN74, their sizes were much smaller than p200. We previously showed that the activity of PI3-kinase was significantly elevated in the p200-positive cells, suggesting that the signaling pathway through p200 may be closely related to the activation of PI3-kinase. We therefore attempted to identify p200. To purify it, we used thiopropylSepharose beads conjugated with the N-SH2 domain of p85a. An extract of NUGC4 cells containing about 500 mg protein was incubated with 400 ml of the affinity matrix. After incubation for 1 h, the beads were extensively washed, and the proteins bound to the beads were eluted with 4% SDS. As shown in Figure 1b , we detected a single band with a molecular weight of approximately 200 kDa by SDS-PAGE.
Identification of p200 as ErbB3
Mass spectral analysis for this band gave 21 peptide peaks, 12 of which corresponded to the fragments of the ErbB3 protein digested with lysylendpeptidase ( Figure  2a and b). To confirm that p200 is ErbB3, we analysed immunoprecipitates with an anti-p85a antibody from extracts of two p200-positive cell lines, KATO-III and NUGC4, by immunoblotting with an antibody specific to ErbB3. As shown in Figure 2c , ErbB3 was readily detectable in these immunoprecipitates, but not in those from p200-negative cell lines. To further confirm the association of PI3-kinase with ErbB3, we tested for the presence of p85 in the immunoprecipitates with antiErbB3 antibody from gastric cancer cell lines. P85 was found to be bound to ErbB3 in p200-positive cells, but not in others (Figure 2c ). These results clearly indicate that ErbB3 binds to PI3-kinase and further provide the possibility that PI3-kinase is activated by ErbB3 in signet-ring cell carcinoma cell lines.
Phosphorylation of ErbB3 in signet-ring cell adenocarcinomas
ErbB3 contains six YXXM motifs, which become the typical binding sites for SH2 domains of p85 after phosphorylation (Hellyer et al., 1998) . As shown in Figure 3a , tyrosine phosphorylation of ErbB3 was high in signet-ring cell carcinoma cell lines, and corresponded with the association of PI3-kinase with ErbB3. Although the expression of ErbB3 was detected in most of highly or moderately differentiated adenocarcinoma cell lines, such as SCH, MKN28, MKN74, and HSC57, tyrosine phosphorylation of ErbB3 was not detected at all in these cells. These results suggest that the tyrosine phosphorylation of ErbB3 may be important for formation of signet-ring cell carcinoma. A signet-ring cell carcinoma cell line, HSC60, showed neither the phosphorylation of ErbB3 nor the association of ErbB3 with PI3-kinase. It is possible that the other factors, which share the same downstream molecules with ErbB3, might contribute to development of signet-ring cell carcinoma in HSC60 cells.
It has been shown that the phosphorylation of ErbB3 can be mediated by the heterodimerization with the other ErbBs. To determine which member of the ErbB Figure 1 Purification of p200. (a) Association of p200 with PI3-kinase in signet-ring cell carcinoma lines. PI3-kinase was immunoprecipitated with anti-p85a antibody from various gastric cancer cells. The immunoprecipitates were electrophoresed on SDS-7.5% polyacrylamide gel, transferred to a PVDF membrane, and subjected to immunoblot analysis with anti-Tyr(P) antibody (upper panel) or anti-p85a antibody (lower panel). (b) Detection of p200. The extract of NUGC4 cells was incubated with 400 ml of thiopropyl-Sepharose beads covalently bound to GST-N-SH2. After washing with RIPA buffer five times, the proteins bound to the beads were eluted with 400 ml of 4% SDS. The eluate were used for silver staining (right panel) and Western blotting with antiTyr(P) antibody (left panel), respectively. The eluate of GST-bound beads was used as a control Role of ErbB3 in poorly differentiated carcinoma M Kobayashi et al family contributes to the activation of ErbB3, we examined the tyrosine phosphorylation of the other ErbBs. Phosphorylation of ErbB2 was detected in all p200-positive cells, suggesting that ErbB2 may be the tyrosine kinase phosphorylating ErbB3 in these cells (Figure 3a) . Some of the differentiated adenocarcinoma cell lines exhibited tyrosine phosphorylation of ErbB2; this was especially obvious in MKN7 cells. The expression level of ErbB3 in MKN7 cells was extremely low, which was about one-eighth as much as that of NUGC4 cells (Figure 3b) , and the signal of its tyrosine (Figure 3c ), suggesting that activation of ErbB2 may be enough for phosphorylation of ErbB3. In contrast, the phosphorylation of EGFR was observed mainly in differentiated adenocarcinomas, but not in signet-ring cell carcinoma cell lines (Figure 3a) . Expression of ErbB4 was undetectable in all of the gastric cancer cell lines tested (data not shown).
A chimeric receptor, ErbB2-B3CT, stimulate the signaling pathway elicited by C-terminal region of ErbB3
The above findings revealed a striking difference in the ErbB3 activation between signet-ring cells and differentiated cells. Hence, we tested effects of enhancement of signaling triggered by phosphorylation of ErbB3 in highly differentiated adenocarcinomas. Since ErbB3 lacks intrinsic tyrosine kinase activity, simple overexpression of this molecule may not be effective. Therefore, we produced a chimeric protein, ErbB2-B3CT. ErbB2(VE) is a constitutively activated oncogenic variant of ErbB2 that exhibits increased tyrosine kinase activity and high autophosphorylation (Figure 4a and b). ErbB2-B3CT contains the extracellular domain, the transmembrane domain, and the kinase domain of ErbB2(VE) (aa l-989) and the carboxyl-terminal region of ErbB3 (aa 979-1342) (Figure 4a ). Having the ErbB3 type of autophosphorylation sites in its carboxyl-terminal region, this molecule may transduce the ErbB3 type of signals instead of the ErbB2 type ones. When transiently expressed in COS-7 cells, this chimeric protein showed a high level of tyrosine phosphorylation, comparable to that of ErbB2(VE) (Figure 4b ).
Dedifferentiated morphology in active-ErbB3-expressing HCC2998 cells
HCC2998 cells are classified into highly differentiated adenocarcinomas that have cell polarity. When these cells are transplanted into nude mice, the tumors formed by these cells show the lumen structure in nude mice (Kobayashi et al., 1999) , indicating that they still retain cell polarity in vivo. In order to test the effect of expression of ErbB2-B3CT in HCC2998 cells, we established stable cell lines expressing this protein. In these stable transformants, ErbB2(VE) or ErbB2-B3CT was constitutively phosphorylated on tyrosine (Figure 5a ). Activation of Akt, a major downstream effector of PI3-kinase, judged by phosphorylation of Ser473, was remarkably enhanced in the cells expressing ErbB2-B3CT ( Figure 5b) ; this was not found in the cells expressing ErbB2(VE), suggesting that ErbB3-type signaling may be activated in ErbB2-B3CT-expressing cells.
As shown in Figure 5c , HCC2998 cells expressing ErbB2-B3CT showed dramatic morphological changes; grew in semisuspension and showed loss of cell-cell contact or cell-matrix interaction, which is characteristic of poorly differentiated cells. In contrast, control cells grew adhering to each other, suggesting that there may be cell-cell interaction in these cells. The cells expressing wild-type ErbB3 did not show any morphologic changes (data not shown). Expression of ErbB2(VE) induced a slight scattering of the cells, but the round-shaped morphology, which is characteristic of ErbB2-B3CT-expressing cells, was not observed. Moreover, the dedifferentiated phenotype of ErbB2-B3CT was completely suppressed by LY294002, an inhibitor of PI3-kinase (Figure 5c ), suggesting that the PI3-kinase signaling pathway has a critical role in the phenotypic change.
Enhancement of expression of MUC1 on cell surface by activation of the ErbB3-PI3-kinase pathway Signet-ring cell carcinoma is characterized by the appearance of mucus droplets in the cell body, with well-developed endoplasmic reticulum and Golgi complexes. These facts prompted us to test the reactivity of (Kufe et al., 1984) . Native signet-ring cell carcinoma cell lines, in which ErbB3 was activated, exhibited high expression of MUC1 on the cell surface (Figure 6b, f) . We therefore examined whether the expression of ErbB2-B3CT affects the expression of mucins. Apparent expression of MUC1 on the cells surface was almost undetectable in parental, or ErbB2(VE)-expressing HCC2998 cells (Figure 6j, l) . In contrast, expression of ErbB2-B3CT in HCC2998 cells resulted in a dramatic increase in the number of cells expressing MUC1 (Figure 6n ). Treatment of these cells with LY294002 completely abolished the MUC1 expression (Figure 6p) . In contrast, a MEK inhibitor, PD98059, did not inhibit the morphologic change and expression of MUC1 induced by expression of ErbB2-B3CT (Figure 6r ). These results suggest that the Ras-MAPK pathway was not important for these cell responses, although activation of Ras-MAP kinase through SHC upon ErbB3 phosphorylation was reported (Altiok et al., 1997) . The expression of a constitutively active PI3-kinase, BD110, enhanced the expression of MUC1 in HCC2998 cells, confirming these results (Figure 6t ). The expression of MUC1 was also diminished by the treatment of LY294002 in native signet-ring carcinoma cells, suggesting that ErbB3-PI3-kinase pathway is indeed important for expression of MUC1 on the cell surface in these cells (Figure 6d, h) . In addition to this, LY294002 induced flattened or differentiated morphology in NUGC4 cells (Figure 6c ). However, KATOIII did not show this response, implying that there were some additional mechanisms that lead to the dedifferentiated status in KATOIII cells. 
Discussion
The major findings of this study are: (1) ErbB3 is phosphorylated on tyrosine in signet-ring carcinoma cell lines; (2) activation of ErbB3 results in the activation of PI3-kinase pathway; (3) activation of ErbB3-PI3-kinase pathway converts phenotypes of highly differentiated adenocarcinomas into those of dedifferentiated ones, including enhancement of the reactivity of anti-MUC1 antibody. These results suggest that ErbB3-PI3-kinase pathway has an important role in the formation of malignant gastric cancer cells. Distinct from other ErbBs, ErbB3 lacks an intrinsic tyrosine kinase activity because of substitutions of three conserved amino acids required for tyrosine kinase activity (Guy et al., 1994) . Therefore, the phosphorylation of ErbB3 may be because of crossactivation by the other ErbBs. The ErbB2/ErbB3 complex has been shown to be preferred to the other possible combinations with ErbB3. The previous reports have demonstrated that combinational activation of ErbB2 and ErbB3 contributed to malignant phenotypes of cancer cells. For example, this combination has been shown to induce cell transformation (Wallasch et al., 1995) , enhanced focus formation in monolayer (Zhang et al., 1996) , and drug resistance (Chen et al., 2000) in NIH3T3 cells. More importantly, coexpression of ErbB3 with ErbB2 promotes anchorage-independent growth in soft agar and tumor formation of breast cancer cells in nude mice (Peter et al., 1999) . These studies suggest that cooperative signaling of ErbB2 and ErbB3 is involved in development of signet-ring cell carcinomas. However, in our studies, the high activation of ErbB2 was seen in both signet-ring cell carcinoma cells and some highly differentiated carcinoma cells including MKN7 cells. In contrast, phosphorylation of ErbB3 was specifically observed in signet-ring cell carcinomas. Therefore, we expected that ErbB3 and the major effecter of ErbB3, PI3-kinase, might be involved in formation of dedifferentiated carcinomas.
The autophosphorylation sites of ErbBs determine the set of downstream effector molecules that are recruited to the receptors upon activation. Ras-MAP kinase pathway is a major signaling route, which is stimulated by the activation of any ErbBs. In contrast to Ras-MAP kinase pathway, a few effectors were shown to be strictly specific to each ErbB. For example, Cbl proto-oncogene is a substrate of EGFR but not the other ErbBs (Levkowitz et al., 1996) , which induces receptor ubiquitination and degradation in lysosome upon phosphorylation of EGFR. Furthermore, PLCg is a specific target of EGFR and ErbB2.
As for PI3-kinase, ErbB3 is the strongest activator among ErbB family receptors. ErbB3 contains six docking and activation sites for PI3-kinase, whereas EGFR and ErbB2 have not been considered to be associated with PI3-kinase. Thus, ErbB3 is considered as an important factor involved in EGF-or neuregulindependent activation of PI3-kinase pathway (Kim et al., 1994; Soltoff et al., 1994) . In order to investigate the role of ErbB3 signaling pathway in dedifferentiated phenotypes, we employed a constitutively active chimeric receptor including the C-terminal phosphorylation site of ErbB3. In a previous study, a chimeric EGFR whose C-terminal autophosphorylation site was replaced by a corresponding region of ErbB3 was shown to generate ErbB3 types of signaling, but not EGFR types, which indicates the importance of the C-terminal regions of ErbBs to generate the receptor-specific signal transduction. EGF-stimulated 32D myeloid cells expressing this chimeric receptor showed the activation of PI3-kinaseAkt pathway (Waterman et al., 1999) . Thus, we believed that the constitutively activated type of ErbB3 chimeric receptor, ErbB3-CT, was a good tool to investigate the role of ErbB3 signaling pathway.
In this study, we observed that the ErbB2-B3CT-expressing cells exhibited enhanced phosphorylation of Akt (Ser473), which may be because of activation of PI3-kinase. Furthermore, the scattered morphology observed in ErbB2-B3CT-expressing cells was suppressed by the treatment of LY294002, suggesting that ErbB3-PI3-kinase pathway contributed to this morphological change. This observation was consistent with our previous finding that the activation of PI3-kinase in HCC2998 cells induces scattered morphology in vitro and converts phenotypes of highly differentiated adenocarcinoma to those of dedifferentiated adenocarcinoma in vivo.
In normal glandular epithelial cells, MUC1 is expressed at the apical surface. This polarized distribution of MUC1 is lost in many cancer cells (Guddo et al., 1998) . Aberrantly glycosylated MUC1 has also been observed in adenocarcinomas. Although the roles of MUC1 in the development or progression of adenocarcinomas are largely unknown, several studies on breast cancers might provide some information. As a result of its long glycosyl chains, MUC1 extends more than 0.1 mm above the cell surface and inhibits contact with its neighboring cells and cell matrix, which makes it easy for cancer cells to metastasize (Komatsu et al., 1997; Kondo et al., 1998) . Therefore, expression of MUC1 on the cell surface may be important for cancer cells to acquire malignant characteristics. We observed that the immunoreactivity of an anti-MUC1 antibody, clone DF3, was enhanced in the ErbB2-B3CT-expressing cells, which was suppressed by treatment with LY294002. The immunoreactivities were also reduced by the treatment of LY294002 in native signet-ring cells, NUGC4 and KATOIII. These results suggest that the ErbB3-PI3-kinase pathway is important for the modulation of MUC1, a marker for malignant tumors. In spite of reduction of MUC1 expression, the morphology was not influenced by the treatment of LY294002 in KATOIII cells, suggesting that MUC1 expression is not always the only factor that contributes to cellular dedifferentiation. Since treatment of NUGC4 cells with LY294002 induced flattening of the cells, activation of PI3-kinase can be a major factor for loss of cell polarity in these cells. Perhaps some additional other factors may be contributing to the loss of cell polarity in KATOIII cells. For example, a point mutation in E-cadherin gene found in KATOIII cells can be a candidate.
Role of ErbB3 in poorly differentiated carcinoma M Kobayashi et al Molecular mechanism underlying the activation of ErbB2 and ErbB3 in signet-ring cell carcinomas is not still clear. One possibility is an autocrine mechanism by a large amount of neuregulin secreted by the signet-ring carcinoma cells, similar to the case with some breast or colon cancer cells. However, we could not detect any effect of the anti-ErbB2 antibody designed to antagonize ligand-dependent activation of ErbB2 on signet-ring carcinoma cells, although this might be because of overexpressing mucins interfering the access of the antibody on cell surface. Further studies are required to clarify the molecular mechanism for the activation of ErbB3 in signet-ring carcinoma cells.
In conclusion, we propose that ErbB3 may be one of the important factors for formation of dedifferentiated carcinoma. Our findings may provide new insight into the function of ErbB3 in gastric cancer.
Materials and methods

Cell lines
Gastrointestinal cancer cell lines were cultured in RPMI1640 medium supplemented with 5% FBS. KATOIII (JCRB0611), NUGC-4 (TKG0049), HSC-39, HSC-58, and HSC-60 (Yanagihara and Tsumuraya, 1992) are human signet-ring cell carcinoma cell lines. AZ-521 (TKG0185), SCH (JCRB0251), MKN7 (TKG0228), MKN28 (JCRB0253), MKN74 (JCRB0255), HSC-57 (Yanagihara and Tsumuraya, 1992) , and SH10-TC (TKG0412) are cell lines from highly or moderately differentiated adenocarcinomas. All cell lines listed above are gastric cancer cell lines. HCC2998 cells (Kobayashi et al., 1999) are a highly differentiated colon cancer cell line. Cells with TKG and JCRB numbers were obtained from the Cancer Cell Repository, Institute of Development, Aging and Cancer, Tohoku University, and the Health Science Research Resources Bank, respectively. HSC cell lines were a gift from the Central Animal Laboratory, National Cancer Research Institute, Japan.
Plasmids used in this study
The ErbB2(VE) gene is a mutant human ErbB2 (Genebank Accession # X 03363) with a substitution of valine 659 by glutamic acid within the transmembrane domain (Wongsasant et al., 1991) . The ErbB2-B3CT gene contains the sequence coding for the carboxyl-terminal region of human ErbB3 (Genebank Accession # M 29366), amino acid 979-1342, combined with the sequence coding for the amino-terminal region of ErbB2(VE), amino acid 1-989, through a HindIII linker, which results in insertion of two amino acids, KL, between the two sequences. Each ErbB gene was then subcloned into a pMIKNeo mammalian expression vector. The fragment coding for N-terminal SH2 domain of p85a (N-SH2) was amplified by PCR and cloned into the sites of BamHI and EcoRI of GEX 2T-3 by use of primers harboring adapter sites of BamHI and EcoRI. Human ErbB3 cDNA and human ErbB2(VE) cDNA were kind gifts from Dr S Higashiyama (Osaka University) and Dr T Yamamoto (University of Tokyo), respectively.
Transient expression and establishment of stable transformants
Transfections were performed by the calcium phosphate method (Tanaka et al., 1999) , with approximately 2 mg DNA for a 35 mm dish. For establishment of stable transformants, HCC2998 cells were transfected with the expression vector carrying the ErbB gene by electroporation at 800 mF capacitance and 240 V by use of a CELL PORATOR Electroporation system I (Life Technologies, Inc.). Neomycin-resistant cells were selected, and the resulting colonies were further cultured for establishment of cell lines.
Antibodies
Monoclonal anti-p85a antibodies AB6 were described previously (Tanaka et al., 1993) . Anti-ErbB3 polyclonal antibody (C-17-G), anti-ErbB2 polyclonal antibody (C-18-G), and anti-EGFR polyclonal antibody (1005-G) were purchased from Santa Cruz Biotechnology. Anti-human MUC1 antibody, clone DF3, was purchased from DAKO. Fluorophore-labeled goat anti-mouse IgG (H+L), Alexa Fluor 488, was purchased from Molecular Probes.
Preparation of affinity beads
GST-NSH2 or GST alone was prepared as described (Lavan et al., 1992) . They were covalently attached to activated thiopropyl Sepharose 6B beads (Sigma) via the sulfhydryl group on the GST (the SH2 domain itself has no sulfhydryl groups). The beads coupled with GST (1 mg/ml) or GST-NSH2 (1.5 mg/ml) were packed in columns, washed with 10 volumes of 5 mm dithiothreitol in 120 mm Tris-HCl, 1 mm EDTA, pH 6.8, to cleave the remaining 2-pyridyl disulfide, and then washed with 30 volumes of 5 mm N-ethylmaleimide in this buffer to block the free sulfhydryl groups. Proteins not bound to the beads were removed with 4% SDS, 2 mm N-ethylmaleimide, 100 mm Tris-HCl, 1 mm EDTA, and 10% glycerol. pH 6.8. Finally the beads were washed extensively with 150 mm NaCl, and 10 mm sodium phosphate, pH 7.5.
Preparation of lysate from NUGC4 cells
Approximately 2 Â 10 9 cells were lysed by mixing with 2.4 ml of 4% SDS in 100 mm HEPES-NaOH, 300 mm NaCl, 8 mm phenylmethylsulfonyl fluoride (PMSF), 8 mm sodium orthovanadate, and 20 mm dithiothreitol (pH 7.5), boiled for 5 min, and sonicated to shear the DNA. After removal of SDSinsoluble material by centrifugation at 100000 g for 5 min, the sulfhydryl groups were alkylated by the addition of 30 mm Nethylmaleimide. Finally, the extract was diluted with 27.6 ml of 1.2% Triton X-100 in 60 mm HEPES-NaOH, 175 mm NaCl, 1.2 mm EGTA, 12 mm sodium phosphate, 12% glycerol, 2 mm MgCl 2 , 0.5 mm sodium orthovanadate, and 0.5 mm PMSF at pH 7.0.
Purification of p200
The lysate of NUGC4 cells was mixed with 0.4 ml of GST-NSH2 beads or GST-beads for 1 h. The beads were washed five times with 10 ml of RIPA buffer (150 mm NaCl, 1% NP40, 0.5% DOC, 0.1% SDS, 50 mm Tris-HCl, pH 7.5) with protease inhibitors (1 mm PMSF, 2 mm leupeptin). Proteins bound to the beads were eluted with 400 ml of SDS buffer (4% SDS, 1 mm EDTA, 1 mm sodium orthovanadate, 100 mm Tris-HCl, pH 6.5, with the protease inhibitors given above). A volume of 40 or 0.4 ml of the eluates was used for silver staining or immunoblotting with antiphosphotyrosine antibody, respectively.
Identification of proteins by peptide mass mapping
The sample was electrophoresed on a 7.5% polyacrylamide gel and transferred onto a polyvinylidene difluoride (PVDF) membrane (Problot, Applied Biosystems). The immobilized proteins were reduced, S-carboxymethylated, and digested in situ with Achromobacter protease I (a Lys-C) (Iwamatsu and Yoshida-Kubomura, 1996) . Molecular mass analyses of Lys-C fragments were performed by matrix-assisted laser desorption/ ionization time-of-flight (MALDI-TOF) mass spectrometry using a PerSeptive Biosystem Voyager-DE/RP. Identification of proteins were carried out by comparison between the molecular weights determined by MALDI-TOF/MS and theoretical peptide masses from the proteins registered in NCBInr (9.19.2001) (Jensen et al., 1996) .
Immunocytochemistry
Cells were fixed with 10% formaldehyde at room temperature for 10 min. The samples were washed three times, preincubated with 1% BSA in PBS, and incubated with the primary antibody diluted in PBS for 2 h. After washing three times, they were incubated with the secondary antibody (Alexa Fluor 488) for 2 h and observed under a fluorescence microscope.
